 Eduardo Davila
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interleukin-1 Receptor-Associated Kinases | 3 | 2020 | 20 | 1.600 |
Why?
| | Melanoma | 5 | 2023 | 620 | 1.450 |
Why?
| | Neoplasms | 6 | 2021 | 2097 | 1.130 |
Why?
| | T-Lymphocytes | 5 | 2023 | 1737 | 1.100 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2021 | 90 | 1.100 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 687 | 1.040 |
Why?
| | Antigens, Neoplasm | 3 | 2017 | 222 | 0.910 |
Why?
| | Melanoma, Experimental | 3 | 2015 | 89 | 0.840 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 615 | 0.840 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 137 | 0.770 |
Why?
| | Cell Engineering | 1 | 2021 | 7 | 0.760 |
Why?
| | Chromones | 2 | 2019 | 35 | 0.740 |
Why?
| | Immunotherapy | 3 | 2021 | 474 | 0.720 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 785 | 0.720 |
Why?
| | Toll-Like Receptor 2 | 3 | 2010 | 110 | 0.710 |
Why?
| | Morpholines | 2 | 2019 | 102 | 0.700 |
Why?
| | Immunotherapy, Adoptive | 5 | 2021 | 184 | 0.700 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1355 | 0.690 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 430 | 0.690 |
Why?
| | Caspase 3 | 1 | 2020 | 235 | 0.650 |
Why?
| | Dendritic Cells | 2 | 2019 | 435 | 0.640 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 206 | 0.630 |
Why?
| | Cancer Vaccines | 1 | 2019 | 137 | 0.600 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1141 | 0.580 |
Why?
| | CD8 Antigens | 1 | 2017 | 69 | 0.580 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 388 | 0.580 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 534 | 0.560 |
Why?
| | Mice, Inbred NOD | 6 | 2021 | 555 | 0.550 |
Why?
| | Phenylurea Compounds | 1 | 2017 | 82 | 0.550 |
Why?
| | Genetic Variation | 1 | 2021 | 870 | 0.520 |
Why?
| | Toll-Like Receptors | 3 | 2012 | 167 | 0.500 |
Why?
| | Mice, SCID | 5 | 2021 | 314 | 0.500 |
Why?
| | Flagellin | 1 | 2015 | 15 | 0.490 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 16 | 0.480 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 616 | 0.480 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 698 | 0.460 |
Why?
| | Pyridines | 1 | 2017 | 425 | 0.450 |
Why?
| | Benzimidazoles | 1 | 2015 | 138 | 0.450 |
Why?
| | Apoptosis | 2 | 2020 | 2363 | 0.430 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 1879 | 0.420 |
Why?
| | T-Lymphocyte Subsets | 3 | 2021 | 383 | 0.420 |
Why?
| | Mice | 13 | 2021 | 14871 | 0.410 |
Why?
| | Animals | 16 | 2021 | 31708 | 0.390 |
Why?
| | Cell Proliferation | 5 | 2020 | 2187 | 0.390 |
Why?
| | Signal Transduction | 3 | 2021 | 4515 | 0.380 |
Why?
| | Lymphocyte Activation | 5 | 2019 | 1037 | 0.370 |
Why?
| | Adoptive Transfer | 2 | 2008 | 195 | 0.310 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 2710 | 0.300 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2008 | 154 | 0.290 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1262 | 0.280 |
Why?
| | Mice, Inbred C57BL | 4 | 2017 | 4694 | 0.250 |
Why?
| | Humans | 17 | 2023 | 114696 | 0.220 |
Why?
| | Gamma Rays | 1 | 2023 | 48 | 0.210 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 56 | 0.210 |
Why?
| | Antigens, CD | 2 | 2021 | 442 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 339 | 0.200 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 56 | 0.200 |
Why?
| | Cell Communication | 2 | 2019 | 280 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.190 |
Why?
| | Antigen Presentation | 2 | 2017 | 188 | 0.190 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3535 | 0.190 |
Why?
| | Skin Neoplasms | 1 | 2008 | 756 | 0.180 |
Why?
| | CD3 Complex | 1 | 2021 | 92 | 0.180 |
Why?
| | Semaphorins | 1 | 2021 | 21 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 117 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2021 | 80 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 129 | 0.180 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 502 | 0.170 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 140 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 172 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 146 | 0.170 |
Why?
| | Cytokines | 3 | 2012 | 1841 | 0.160 |
Why?
| | Mice, Transgenic | 2 | 2017 | 1950 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 28 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 520 | 0.160 |
Why?
| | Leukemia | 1 | 2021 | 209 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 849 | 0.150 |
Why?
| | HLA-A2 Antigen | 2 | 2010 | 36 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 385 | 0.150 |
Why?
| | CD55 Antigens | 1 | 2017 | 27 | 0.140 |
Why?
| | Protein Binding | 2 | 2021 | 1890 | 0.140 |
Why?
| | 5'-Nucleotidase | 1 | 2017 | 35 | 0.140 |
Why?
| | Genes, MHC Class I | 1 | 2017 | 32 | 0.140 |
Why?
| | Receptors, Virus | 1 | 2017 | 75 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 195 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 695 | 0.140 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1003 | 0.140 |
Why?
| | Immunomodulation | 1 | 2017 | 84 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 427 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 139 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2017 | 323 | 0.130 |
Why?
| | Toll-Like Receptor 5 | 1 | 2015 | 14 | 0.120 |
Why?
| | TNF Receptor-Associated Factor 6 | 1 | 2015 | 3 | 0.120 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 22 | 0.120 |
Why?
| | Nitrophenols | 1 | 2015 | 32 | 0.120 |
Why?
| | Jurkat Cells | 1 | 2015 | 128 | 0.120 |
Why?
| | MCF-7 Cells | 1 | 2015 | 105 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 50 | 0.120 |
Why?
| | Vincristine | 1 | 2015 | 98 | 0.120 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 228 | 0.120 |
Why?
| | Protein Stability | 1 | 2015 | 157 | 0.120 |
Why?
| | Drug Synergism | 1 | 2015 | 316 | 0.110 |
Why?
| | Cell Survival | 2 | 2015 | 1021 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2017 | 1083 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 172 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2015 | 352 | 0.110 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 19 | 0.100 |
Why?
| | Receptors, Antigen | 1 | 2012 | 10 | 0.100 |
Why?
| | Cell Growth Processes | 1 | 2012 | 51 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2015 | 591 | 0.100 |
Why?
| | Piperazines | 1 | 2015 | 309 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1230 | 0.100 |
Why?
| | Sulfonamides | 1 | 2015 | 445 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2011 | 4 | 0.090 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.090 |
Why?
| | Male | 5 | 2021 | 55604 | 0.090 |
Why?
| | Cell Movement | 1 | 2015 | 869 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3346 | 0.090 |
Why?
| | Perforin | 1 | 2010 | 18 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 785 | 0.090 |
Why?
| | Thymoma | 1 | 2010 | 30 | 0.090 |
Why?
| | Female | 5 | 2021 | 59518 | 0.090 |
Why?
| | Granzymes | 1 | 2010 | 40 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2017 | 3886 | 0.090 |
Why?
| | T-Box Domain Proteins | 1 | 2010 | 92 | 0.090 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 201 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2021 | 2570 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 273 | 0.080 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 212 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 329 | 0.080 |
Why?
| | Phosphorylation | 1 | 2012 | 1569 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 360 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2010 | 719 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1518 | 0.070 |
Why?
| | B7-2 Antigen | 1 | 2005 | 25 | 0.060 |
Why?
| | CD56 Antigen | 1 | 2005 | 34 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2005 | 47 | 0.060 |
Why?
| | Synovial Membrane | 1 | 2005 | 75 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 150 | 0.060 |
Why?
| | Clone Cells | 1 | 2005 | 247 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2005 | 274 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 430 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 594 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 122 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2320 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Graft vs Tumor Effect | 1 | 2021 | 8 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 62 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 838 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2637 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 377 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 959 | 0.040 |
Why?
| | Phenotype | 1 | 2021 | 2796 | 0.030 |
Why?
| | Aged | 1 | 2021 | 19074 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 26737 | 0.010 |
Why?
|
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|